Inhibitor Therapeutics (INTI) Other Operating Expenses (2012 - 2020)
Inhibitor Therapeutics' (INTI) quarterly Other Operating Expenses came in at -$10.0 in Q4 2020, down 100.01% on a QoQ basis from $117324.0 in Q2 2013.
Inhibitor Therapeutics (INTI) Other Operating Expenses (2012 - 2020) Analysis & Trends
Inhibitor Therapeutics (INTI) has 3 years of Other Operating Expenses data on file, last reported at -$10.0 in Q4 2020.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$10.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was -$10.0 (changed N/A YoY) and the FY2023 annual result came in at $300000.0, down 97.62% from the prior year.
- Other Operating Expenses fell to -$10.0 in Q4 2020, from $117324.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$10.0 in Q4 2020 to a low of -$10.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -10.00 |
| Jun 30, 2013 | 117,324.00 |
| Dec 31, 2012 | -31,625.00 |